Beijing Wista Pharma Co., Ltd.

Main purpose: According to the relevant provisions of bioequivalence test, Betahistine Mesylate Tablets (trade name: Minshilang®, specification: 6mg) of which Eisai (China) Pharmaceutical Co., Ltd. is the licensee was selected as the reference preparation, and the test preparation Betahistine Mesylate Tablets (specification: 6mg) provided by Beijing Zimeng Pharmaceutical Technology Co., Ltd. was subjected to human bioequivalence test of fasting and postprandial administration, to compare whether the absorption rate and degree of the drug in the test preparation were within the acceptable range with the reference preparation, and to evaluate the bioequivalence of the two preparations under fasting and postprandial administration conditions. Secondary purpose: To observe the safety of oral administration of the test preparation Betahistine Mesylate Tablets (specification: 6mg) and the reference preparation Betahistine Mesylate Tablets (trade name: Minshilang®, specification: 6mg) by healthy volunteers.

Primary objective: To observe the pharmacokinetic characteristics of the test preparation Eperisone Hydrochloride Tablets (Specification: 50 mg; Manufacturer: Baiyunshan Dongtai Shangqiu Pharmaceutical Co., Ltd.) and the reference preparation Eperisone Hydrochloride Tablets (Trade name: Myona®; Specification: 50 mg; Licensee and Manufacturer: Eisai (China) Pharmaceutical Co., Ltd.) after a single oral administration in the fasting/postprandial state in healthy Chinese subjects, and to evaluate the bioequivalence of the two preparations in the fasting/postprandial state. Secondary objective: To observe the safety of the test preparation Eperisone Hydrochloride Tablets and the reference preparation Eperisone Hydrochloride Tablets (Myona®) in healthy Chinese subjects.